Predictive value of inflammatory indices LMR, PLR and NLR in patients with muscle-invasive bladder cancer

Abstract

BACKGROUND: Increasing the efficiency of predicting the results of treatment of patients with bladder cancer is one of the important tasks of modern urology.

AIM: Our aim was to identify and evaluate the association between the most significant clinical, morphological and immunological markers and survival of muscle-invasive bladder cancer patients treated with radical cystectomy. We also developed an algorithm for diagnosis and treatment of patients with muscle-invasive bladder cancer.

MATERIALS AND METHODS: This retrospective study included 100 muscle-invasive bladder cancer patients, who underwent radical cystectomy between 1995 and 2013. The study endpoints were overall survival.

RESULTS: Univariable analysis revealed that continuous (Lymphocyte-monocyte ratio), PLR (platelet-lymphocyte ratio) и NLR (neutrophil-lymphocyte ratio) were significantly associated with overall survival. On multivariable regression model analysis, continuous LMR, NLR, and PLR independently predicted both endpoints.

CONCLUSIONS: Our findings indicate that the cheap and simple blood-based biomarkers may be valuable in identifying muscle-invasive bladder cancer patients treated with radical cystectomy, who are at higher risk of all-cause mortality.

Keywords

bladder cancer / inflammatory markers / radical cystectomy

References

[1] Antoni S, Ferlay J, Soerjomataram I, et al. bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. DOI: 10.1016/j.eururo.2016.06.010

[2] Antoni S., Ferlay J., Soerjomataram I., et al. Bladder cancer incidence and mortality: a global overview and recent trends // Eur Urol 2017. Vol. 71, No. 1. P. 96–108. DOI: 10.1016/j.eururo.2016.06.010

[3] Kaprin AD, Starinskiy VV, Shahzadova AO, editors. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. Moscow: MNIOI Gercena PA; 2020. 239 p.

[4] Состояние онкологической помощи населению России в 2019 году / под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.

[5] Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3): 289–293. DOI: 10.1007/s00345-009-0383-3

[6] Ploeg M., Aben K.K.H., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world // World J Urol. 2009. Vol. 27, No. 3. P. 289–293. DOI: 10.1007/s00345-009-0383-3

[7] Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71(3):462–475. DOI: 10.1016/j.eururo.2016.06.020

[8] Alfred Witjes J., Lebret T., Compérat E.M., et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer // Eur Urol. 2017. Vol. 71, No. 3. P. 462–475. DOI: 10.1016/j.eururo.2016.06.020

[9] Sharma A, Subudhi SK, Blando J, et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019;25(4):1233–1238. DOI: 10.1158/1078-0432.CCR-18-0762

[10] Sharma A., Subudhi S.K., Blando J., et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers // Clin Cancer Res. 2019. Vol. 25, No. 4. P. 1233–1238. DOI: 10.1158/1078-0432.CCR-18-0762

[11] Oh BS, Jang JW, Kwon JH, et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. DOI: 10.1186/1471-2407-13-78

[12] Oh B.S., Jang J.W., Kwon J.H., et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma // BMC Cancer 2013. Vol. 13. P. 78. DOI: 10.1186/1471-2407-13-78

[13] Gurol G, Ciftci IH, Terizi HA, et al. Are there standardized cutoff values for neutrophil-lymphocyte ratios in bacteremia or sepsis? J Microbiol Biotechnol. 2015;25(4):521–525. DOI: 10.4014/jmb.1408.08060

[14] Gurol G., Ciftci I.H., Terizi H.A., et al. Are there standardized cutoff values for neutrophil-lymphocyte ratios in bacteremia or sepsis? // J Microbiol Biotechnol 2015. Vol. 25, No. 4. P. 521–525. DOI: 10.4014/jmb.1408.08060

[15] Chen ZY, Ragha K, Lieu CH, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015;112(6):1088–1097. DOI: 10.1038/bjc.2015.61

[16] Chen Z.Y., Raghav K., Lieu C.H., et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer // Br J Cancer 2015. Vol. 112, No. 6. P. 1088–1097. DOI: 10.1038/bjc.2015.61

[17] Gakis G. The role of inflammation in bladder cancer. Adv Exp Med Biol. 2014;816:183–196. DOI: 10.1007/978-3-0348-0837-8_8

[18] Gakis G. The role of inflammation in bladder cancer // Adv Exp Med Biol. 2014. Vol. 816. P. 183–196. DOI: 10.1007/978-3-0348-0837-8_8

[19] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. DOI: 10.1038/nature07205

[20] Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation // Nature. 2008. Vol. 454, No. 7203. P. 436–444. DOI: 10.1038/nature07205

[21] Balkarli A, Kucuk A, Babur H, Erbasan F. Neutrophil/lymphocyte ratio and mean platelet volume in Behcet’s disease. Eur Rev Med Pharmacol Sci. 2016;20(14):3045–3050.

[22] Balkarli A., Kucuk A., Babur H., Erbasan F. Neutrophil/lymphocyte ratio and mean platelet volume in Behcet’s disease // Eur Rev Med Pharmacol Sci. 2016. Vol. 20, No. 14. P. 3045–3050.

[23] Wasilewski J, Pyka Ł, Hawranek M, et al. Prognostic value of neutrophil tolymphocyte ratio in predicting long-term mortality in patients with ischemic and nonischemic heart failure. Pol Arch Med Wewn. 2016;126(3):166–173. DOI: 10.20452/pamw.3316

[24] Wasilewski J., Pyka Ł., Hawranek M., et al. Prognostic value of neutrophil tolymphocyte ratio in predicting long-term mortality in patients with ischemic and nonischemic heart failure // Pol Arch Med Wewn. 2016. Vol. 126, No. 3. P. 166–173. DOI: 10.20452/pamw.3316

[25] Sui X, Lei L, Chen L, et al. Inflammatory Microenvironment in the Initiation and Progression of Bladder Cancer. Oncotarget. 2017;8(54):93279–93294. DOI: 10.18632/oncotarget.21565

[26] Sui X., Lei L., Chen L., et al. Inflammatory Microenvironment in the Initiation and Progression of Bladder Cancer // Oncotarget. 2017. Vol. 8, No. 54. P. 93279–93294. DOI: 10.18632/oncotarget.21565

[27] Kim J, Bae JS. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm. 2016;2016:6058147. DOI: 10.1155/2016/6058147

[28] Kim J., Bae J.S. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment // Mediators Inflamm. 2016. Vol. 2016. P. 6058147. DOI: 10.1155/2016/6058147

[29] Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2): 137–148. DOI: 10.1016/j.immuni.2004.07.017

[30] Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting // Immunity. 2004. Vol. 21, No. 2. P. 137–148. DOI: 10.1016/j.immuni.2004.07.017

[31] Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104(10):3967–3972. DOI: 10.1073/pnas.0611618104

[32] Sharma P., Shen Y., Wen S., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma // Proc Natl Acad Sci USA. 2007. Vol. 104, No. 10. P. 3967–3972. DOI: 10.1073/pnas.0611618104

[33] Morizawa Y, Miyake M, Shimada K, at al. Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer. Cancer Invest. 2018;36(7):395–405. DOI: 10.1080/07357907.2018.1506800

[34] Morizawa Y., Miyake M., Shimada K., at al. Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer // Cancer Invest. 2018. Vol. 36, No. 7. P. 395–405. DOI: 10.1080/07357907.2018.1506800

[35] Miyake M, Hori S, Morizawa Y, et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia. 2016;18(10):636–646. DOI: 10.1016/j.neo.2016.08.002

[36] Miyake M., Hori S., Morizawa Y., et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer // Neoplasia. 2016. Vol. 18, No. 10. P. 636–646. DOI: 10.1016/j.neo.2016.08.002

[37] Khaki AR, Agarwal N, Pal SK, Grivas P. Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. Cancer. 2020;126(20):4446–4450. DOI: 10.1002/cncr.33068

[38] Khaki A.R., Agarwal N., Pal S.K., Grivas P. Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest // Cancer. 2020. Vol. 126, No. 20. P. 4446–4450. DOI: 10.1002/cncr.33068

[39] Kaiser J, Li H, North SA, et al. The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. Bladder Cancer. 2018;4(2):185–194. DOI: 10.3233/BLC-170133

[40] Kaiser J., Li H., North S.A., et al. The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study // Bladder Cancer. 2018. Vol. 4, No. 2. P. 185–194. DOI: 10.3233/BLC-170133

[41] Rajwa P, Życzkowski M, Paradysz A, et al. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci. 2018;22(10):3027–3037. DOI: 10.26355/eurrev_201805_15060

[42] Rajwa P., Życzkowski M., Paradysz A., et al. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy // Eur Rev Med Pharmacol Sci. 2018. Vol. 22, No. 10. P. 3027–3037. DOI: 10.26355/eurrev_201805_15060

[43] Tamura S, Wang Y, Veeneman B, et al. Molecular correlates of in vitro responses to dacomitinib and afatinib in bladder cancer. Bladder Cancer. 2018;4(1):77–90. DOI: 10.3233/BLC-170144

[44] Tamura S., Wang Y., Veeneman B., et al. Molecular correlates of in vitro responses to dacomitinib and afatinib in bladder cancer // Bladder Cancer. 2018. Vol. 4, No. 1. P. 77–90. DOI: 10.3233/BLC-170144

[45] Zhang J, Zhou X, Ding H, et al. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer. BMC Urol. 2020;20(1):31. DOI: 10.1186/s12894-020-00602-9

[46] Zhang J., Zhou X., Ding H., et al. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer // BMC Urol. 2020. Vol. 20, No. 1. P. 31. DOI: 10.1186/s12894-020-00602-9

[47] Ma X, Li H, Chen L, et al. Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram. Sci Rep. 2016;6:23846. DOI: 10.1038/srep23846

[48] Ma X., Li H., Chen L., et al. Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram // Sci Rep. 2016. Vol. 6. P. 23846. DOI: 10.1038/srep23846

[49] Neal CP, Cairns V, Jones MJ, et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases. Med Oncol. 2015;32(5):144. DOI: 10.1007/s12032-015-0590-2

[50] Neal C.P., Cairns V., Jones M.J., et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases // Med Oncol. 2015. Vol. 32, No. 5. P. 144. DOI: 10.1007/s12032-015-0590-2

[51] D’Andrea D, Moschini M, Gust KM, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. J Surg Oncol. 2017;115(4):455–461. DOI: 10.1002/jso.24521

[52] D’Andrea D., Moschini M., Gust K.M., et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy // J Surg Oncol. 2017. Vol. 115, No. 4. P. 455–461. DOI: 10.1002/jso.24521

[53] Zhang GM, Zhu Y, Luo L, et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumour Biol. 2015;36(11):8537–8543. DOI: 10.1007/s13277-015-3613-x

[54] Zhang G.M., Zhu Y., Luo L., et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy // Tumour Biol. 2015. Vol. 36, No. 11. P. 8537–8543. DOI: 10.1007/s13277-015-3613-x

[55] Bhindi B, Hermanns T, Wei Y, et al. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer. 2016;114(2):207–212. DOI: 10.1038/bjc.2015.432

[56] Bhindi B., Hermanns T., Wei Y., et al. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy // Br J Cancer. 2016. Vol. 114, No. 2. P. 207–212. DOI: 10.1038/bjc.2015.432

RIGHTS & PERMISSIONS

Gorelov A.I., Zhuravskii D.A., Gorelova A.A.